دانلود کتاب ایمونولوژی و ایمونوتراپی تومور
Tumor Immunology and Immunotherapy, 1ed

Patients are beginning to benefit from antibody based, cellular and vaccine approaches that are effective against genetically diverse and therapy-resistance cancers. BCG immunotherapy is now being used as a first line treatment for human bladder cancer and the introduction of prophylactic vaccination against Hepatitis B and HPV cancers is starting to show positive results. Following recent FDA approval for a vaccination against prostate cancer, and optimistic results in clinical trials for a vaccine targeting cancer antigens in lung cancer, cancer immunotherapy is now significantly impacting patient clinical management.

Tumor Immunology and Immunotherapy provides an up-to-date and comprehensive account of cancer immunity and immunotherapy. It discusses our adaptive and innate immunity to cancer, the mechanisms underpinning our immune response, current approaches to cancer immunotherapy, and how tumour and host responses can circumvent effective anti-cancer immunity.

The book examines recent results, publications and current areas of interest including ‘immune editing’ and the specific issues that are affecting the research and development of vaccines, providing insight into how these problems may be overcome, as viewed by world leaders in the field. Tumor Immunology and Immunotherapy will appeal to clinicians working in oncology and cancer immunotherapy, and research scientists including PhD and masters students, post-doctoral researchers and senior investigators.

Review

About the Author

Contents

Chapter 1 Adaptive Tcell immunity and tumor antigen recognition
Chapter 2 Impact of ageing and body mass on cancer immunotherapy outcomes
Chapter 3 The potential of natural killer cells in cancer immunotherapy
Chapter 4 The tumor microenvironment: The role of tumorassodated macrophages in cancer progression and responses to therapy
Chapter 5 ‘Hard’ and ‘soft’ loss of MHC classIexpression in cancer cells
Chapter 6 Modulation of the adaptive immune system through chronic inflammation and Tregulatory responses
Chapter 7 Myeloidderived suppressor cells: Immunesuppressive cells that facilitate tumor progression and promote and deter cancerassociated inflammation
Chapter 8 Triggering death receptors to promote cancer cell death
Chapter 9 Identification of tumor antigens for clinical evaluation
Chapter 10 Viral antigens as targets for prophylactic and therapeutic intervention in cancer
Chapter 11 HER2/neu as a target for vaccine and antibodydirected therapies
Chapter 12 Preclinical evaluation of immunotherapy: The case for prostate cancer and the TRAMP model
Chapter 13 Tumorassodated antigens characterized in a conceptual framework of biology, microenvironment, and therapy
Chapter 14 Predictive biomarkers to better select patients for cancer immunotherapy
Chapter 15 Viral platforms for expression of tumor antigens in cancer immunotherapy
Chapter 16 Translating research into clinical practice: lessons from the immunology and immunotherapy of haemopoietic malignancies
Chapter 17 DNA vaccines
Chapter 18 Programming the immune system through childhood infections: MUC1tumorassodated antigen (TAA) as a diseaseassociated antigen (DAA)
Chapter 19 Vaccination against myeloid leukaemias using newly defined antigens
Chapter 20 Immunecheckpoint blockade in cancer immunotherapy
Chapter 21 Multipeptide cancer vaccines for clinical application
Chapter 22 Adoptive Tcell therapy using TILs for the treatment of metastatic melanoma
Chapter 23 Chimeric antigen receptor gene therapy in cancer
Chapter 24 The vaccinal effect of monoclonal antibodies in cancer therapy
Chapter 25 Antibody therapies: defining appropriate cell surface epitopes for targeting tumors
Chapter 26 Adoptive lymphocyte (stem cell) therapy in cancer
Chapter 27 Cancer stem cells (CSCs) and epithelialtomesenchymal transition (EMT): Tumor cell plasticity challenges immunotherapy
Chapter 28 Immune escape and ageing of the immune system compromises the immune response to tumor antigens